Clarus Therapeutics Holdings, Inc. (CRXTQ) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Clarus Therapeutics Holdings, Inc. (CRXTQ) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 68/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 18. März 2026Clarus Therapeutics Holdings, Inc. (CRXTQ) Gesundheitswesen & Pipeline-Uebersicht
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company specializing in oral testosterone replacement therapy, primarily JATENZO, targeting hypogonadal men. Facing financial challenges, the company filed for Chapter 11 reorganization and now operates on the OTC market, navigating a competitive landscape of established pharmaceutical companies.
Investmentthese
Clarus Therapeutics Holdings, Inc. faces significant challenges following its Chapter 11 filing in September 2022. The company's primary asset, JATENZO, targets a specific market segment within testosterone replacement therapy. The company's gross margin stands at 80.5%. However, the company's profit margin is -404.9%. Trading on the OTC market introduces liquidity and regulatory risks. Potential investors should carefully consider the implications of the bankruptcy proceedings and the inherent risks associated with OTC-listed companies before making any investment decisions. The company's future hinges on successful restructuring and potential strategic partnerships.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross Margin of 80.5% indicates strong potential profitability on sales before operating expenses.
- Filed for Chapter 11 reorganization on September 5, 2022, impacting financial stability and future operations.
- Offers JATENZO, an oral testosterone replacement therapy, targeting the hypogonadal men market.
- Trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
- Profit Margin of -404.9% signals significant financial losses and operational inefficiencies.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary oral formulation of testosterone (JATENZO).
- Licensing agreements for potential new therapies.
- Established presence in the testosterone replacement market.
- Gross margin of 80.5%.
Schwaechen
- Chapter 11 bankruptcy filing.
- Negative profit margin (-404.9%).
- Limited product portfolio concentrated on JATENZO.
- Trading on the OTC market with associated risks.
Katalysatoren
- Ongoing: Restructuring efforts under Chapter 11 bankruptcy proceedings could lead to improved financial stability and operational efficiency.
- Upcoming: Potential FDA approvals for new therapies developed through licensing agreements with HavaH Therapeutics and McGill University.
- Ongoing: Strategic partnerships or acquisitions to expand the product portfolio and market reach.
Risiken
- Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.
- Potential: Competition from established pharmaceutical companies and generic drug manufacturers.
- Potential: Regulatory challenges and potential changes in guidelines for testosterone replacement therapy.
- Ongoing: Limited financial disclosure and transparency due to OTC listing.
- Potential: Low trading volume and liquidity on the OTC market.
Wachstumschancen
- Expansion of JATENZO Market Share: Clarus has the opportunity to increase the market share of JATENZO within the oral testosterone replacement therapy segment. This can be achieved through targeted marketing campaigns, improved patient education, and strategic partnerships with healthcare providers. The global testosterone replacement therapy market is projected to reach $2.1 billion by 2027, providing a substantial market for JATENZO to penetrate further. Timeline: Ongoing.
- Development of New Androgen Therapies: The licensing agreement with HavaH Therapeutics presents an opportunity to develop novel androgen therapies for inflammatory breast disease and certain forms of breast cancer. Successful development and commercialization of these therapies could diversify Clarus's product portfolio and tap into new therapeutic areas. The market for breast cancer therapies is estimated to reach $30 billion by 2028. Timeline: 3-5 years.
- Commercialization of CoQ10 Deficiency Treatment: The license agreement with McGill University to develop and commercialize technology for treating CoQ10 deficiencies offers another avenue for growth. CoQ10 deficiencies are associated with various neurological and muscular disorders, representing a significant unmet medical need. The market for CoQ10 supplements and treatments is growing, driven by increasing awareness of its health benefits. Timeline: 3-5 years.
- Strategic Partnerships and Acquisitions: Clarus could pursue strategic partnerships or acquisitions to expand its product portfolio, access new markets, or enhance its research and development capabilities. Collaborations with other pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of new therapies. The pharmaceutical industry is characterized by frequent mergers and acquisitions, providing opportunities for Clarus to participate in consolidation. Timeline: Ongoing.
- Restructuring and Financial Turnaround: Successful restructuring under Chapter 11 could provide Clarus with a fresh start and the opportunity to streamline its operations, reduce its debt burden, and improve its financial performance. A successful turnaround could restore investor confidence and unlock the company's long-term growth potential. The timeline for restructuring is dependent on the bankruptcy court proceedings and the company's ability to negotiate with creditors. Timeline: 1-2 years.
Chancen
- Expansion of JATENZO market share.
- Development and commercialization of new androgen therapies.
- Commercialization of CoQ10 deficiency treatment.
- Strategic partnerships and acquisitions.
Risiken
- Competition from established pharmaceutical companies.
- Regulatory challenges and potential changes in guidelines.
- Generic competition for JATENZO.
- Economic downturn impacting healthcare spending.
Wettbewerbsvorteile
- Proprietary oral formulation of testosterone undecanoate (JATENZO).
- Licensing agreements for novel androgen therapies and CoQ10 deficiency treatments.
- Established presence in the testosterone replacement therapy market.
- Intellectual property protection for JATENZO and other pipeline products.
Ueber CRXTQ
Founded in 2003 and based in Northbrook, Illinois, Clarus Therapeutics Holdings, Inc. is a pharmaceutical company dedicated to developing and commercializing oral testosterone replacement therapies. Its primary product, JATENZO, is a soft gel oral formulation of testosterone undecanoate designed to treat hypogonadal men. This therapy offers an alternative to traditional testosterone replacement methods, such as injections or topical gels. In addition to JATENZO, Clarus has licensing agreements with HavaH Therapeutics to develop androgen therapies for inflammatory breast disease and certain forms of breast cancer. They also have a license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. However, on September 5, 2022, Clarus Therapeutics Holdings, Inc. and its affiliate filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware, impacting its operational and financial stability. The company now trades on the OTC market.
Was das Unternehmen tut
- Develop and commercialize oral testosterone replacement therapy.
- Offer JATENZO, a soft gel oral formulation of testosterone undecanoate.
- Target hypogonadal men with testosterone deficiency.
- Hold licensing agreements for androgen therapies targeting inflammatory breast disease and breast cancer.
- Collaborate with McGill University to develop treatments for CoQ10 deficiencies.
- Operate in the pharmaceutical industry, subject to regulatory approvals and market competition.
Geschaeftsmodell
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market JATENZO for testosterone replacement therapy.
- Generate revenue through sales of JATENZO.
- License technology and collaborate with other companies for new product development.
Branchenkontext
Clarus Therapeutics Holdings, Inc. operates within the drug manufacturing industry, focusing on therapies for hormone replacement. The market for testosterone replacement therapy is driven by an aging population and increasing awareness of hypogonadism. However, the industry is highly competitive, with established pharmaceutical companies and generic drug manufacturers vying for market share. Clarus faces competition from companies offering alternative testosterone delivery methods, such as injections, topical gels, and patches. The company's Chapter 11 filing adds another layer of complexity in a sector characterized by stringent regulatory requirements and high research and development costs.
Wichtige Kunden
- Hypogonadal men diagnosed with testosterone deficiency.
- Healthcare providers who prescribe testosterone replacement therapy.
- Pharmacies that dispense JATENZO.
- Patients seeking oral alternatives to traditional testosterone treatments.
Finanzdaten
Chart & Info
Clarus Therapeutics Holdings, Inc. (CRXTQ) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CRXTQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CRXTQ.
Kursziele
Wall-Street-Kurszielanalyse fuer CRXTQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CRXTQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Robert E. Dudley
CEO
Robert E. Dudley serves as the CEO of Clarus Therapeutics Holdings, Inc. His leadership experience includes managing teams and overseeing the development and commercialization of pharmaceutical products. His expertise lies in the pharmaceutical industry, with a focus on hormone replacement therapies and related therapeutic areas. He is responsible for guiding the company through its current financial challenges and strategic restructuring efforts.
Erfolgsbilanz: Under Robert E. Dudley's leadership, Clarus Therapeutics Holdings, Inc. has focused on expanding the market reach of JATENZO and pursuing licensing agreements for new therapies. However, the company filed for Chapter 11 reorganization during his tenure, presenting a significant challenge to his leadership and the company's future prospects. He is currently focused on navigating the restructuring process and seeking opportunities for financial recovery.
CRXTQ OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. These securities often belong to companies that are distressed, undergoing bankruptcy, or have limited financial disclosure. Companies in this tier may not meet minimum financial standards and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other securities carries a higher degree of risk due to the lack of transparency and liquidity.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for significant price volatility.
- Risk of delisting or suspension of trading.
- Uncertainty related to Chapter 11 bankruptcy proceedings.
- Verify the company's current financial status and bankruptcy proceedings.
- Review any available financial reports and disclosures.
- Assess the trading volume and bid-ask spread for CRXTQ.
- Research the company's management team and their experience.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before making any investment decisions.
- Established presence in the testosterone replacement therapy market prior to bankruptcy.
- Proprietary oral formulation of testosterone (JATENZO).
- Licensing agreements for potential new therapies.
- Continued operations during Chapter 11 reorganization.
CRXTQ Healthcare Aktien-FAQ
What are the key factors to evaluate for CRXTQ?
Clarus Therapeutics Holdings, Inc. (CRXTQ) currently holds an AI score of 68/100, indicating moderate score. Key strength: Proprietary oral formulation of testosterone (JATENZO).. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy proceedings create uncertainty about the company's future viability.. This is not financial advice.
How frequently does CRXTQ data refresh on this page?
CRXTQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRXTQ's recent stock price performance?
Recent price movement in Clarus Therapeutics Holdings, Inc. (CRXTQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary oral formulation of testosterone (JATENZO).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRXTQ overvalued or undervalued right now?
Determining whether Clarus Therapeutics Holdings, Inc. (CRXTQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRXTQ?
Before investing in Clarus Therapeutics Holdings, Inc. (CRXTQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CRXTQ to a portfolio?
Potential reasons to consider Clarus Therapeutics Holdings, Inc. (CRXTQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary oral formulation of testosterone (JATENZO).. Additionally: Licensing agreements for potential new therapies.. The AI-driven MoonshotScore of 68/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CRXTQ?
Yes, most major brokerages offer fractional shares of Clarus Therapeutics Holdings, Inc. (CRXTQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CRXTQ's earnings and financial reports?
Clarus Therapeutics Holdings, Inc. (CRXTQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CRXTQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available sources and may be limited due to the company's OTC listing and Chapter 11 status.
- Financial data may not be fully up-to-date due to the bankruptcy proceedings.